Morningstar

Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...
Nasdaq

Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study

Bayer AG BAYRY announced positive top-line results of the phase III study, OASIS 3, evaluating the efficacy and long-term safety of pipeline candidate elinzanetant compared to placebo. Elinzanetant, a ...
Nasdaq

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1 In OASIS 1 and OASIS 2, ...
Pharmabiz

Bayer presents positive results from global phase I first-in-human, dose-escalation PAnTHa study at ASCO GU 2026

Bayer presents positive results from global phase I first-in-human, dose-escalation PAnTHa study at ASCO GU 2026: Berlin, Germany Monday, March 2, 2026, 13:00 Hrs [IST] Bayer anno ...
GEN

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering ...